Safety and Performance Study of the CAdiscTM-L Lumbar Spinal Disc Replacement Device For CE Marking

Inclusion Criteria: * Male or non pregnant, non-lactating female * Aged between 25-65 years (inclusive) * BMI \< 35 * Preoperative ODI \> 30 points * Chronic low back pain, and is in the opinion of the investigator a suitable candidate for anterior lumbar surgery * Completed at least 6 months of conservative treatment without obtaining adequate symptomatic relief * Degenerative disc changes at a single level between L3 - L4, or L4 - L5, or L5 - S1 as confirmed by positive discography and visualized by X-Ray, CT or MRI scan and/or with one or more of the following: * Decrease in disc height \< 50% (or up to 80% and no benefit from facet injections) * Annular thickening * Herniated nucleus pulpous * Subject is able to give voluntary, written informed consent to participate in this investigation and from whom written consent must be obtained prior to enrolment. Exclusion Criteria: * Back or leg pain of unknown aetiology * Radicular or sciatic pain which is more severe than low back pain * Previous lumbar spinal surgery which could affect the trial outcome (e.g., disc replacement) * Obvious signs of psychological or worker's compensation or litigation claim elements to their condition, or are actively engaged in such activities * Subject is unwilling or unable to give consent or adhere to the follow-up programme * Active infection or metastatic disease * Non-degenerative spondylolisthesis * Degenerative spondylolisthesis \> grade 1 * Known allergy to any of the implant materials * Osteoporosis (if suspected to be confirmed by bone density being 2.5SD below normal as assessed using DEXA analysis in post-menopausal females if suggested by X-ray or other risk factors) * Osteopenia * Bony lumbar stenosis * Pars defect * Isolated radicular compression syndromes, especially due to disc herniation * Clinically compromised vertebral bodies at the affected levels due to current or past trauma * Subject is skeletally immature as determined by the investigator * Subject has participated in another clinical investigation or study with an investigational medical device within the last 60 days * Concomitant medications that are known significantly to interfere with bone/soft tissue healing, e.g. steroids. * Uncorrected iliac, aorto-iliac, or aortic aneurysm disease. * Spinal instability (\> 3mm translation or \> 5° angulation) confirmed by functional radiological assessment. * Degenerative disc changes at the L6 - S1 level